Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.73 |
| ▸ | ITK | Q08881 | 3/20 | 0.73 |
| ▸ | SYK | P43405 | 10/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21108861 | 0.95 | EGFR (0.80) | EGFRITKSYKMAPK8MAPK9 | |
| SCHEMBL14658806 | 0.91 | MAPK8 (0.77) | EGFRITKSYKMAPK8MAPK9 | |
| SCHEMBL3175075 | 0.88 | MAPK8 (0.82) | EGFRITKSYKMAPK8MAPK9 | |
| SCHEMBL763232 | 0.87 | SYK (0.69) | EGFRSYKMAPK8MAPK9 | |
| SCHEMBL15161204 | 0.87 | SYK (0.66) | EGFRITKSYKMAPK8MAPK9 | |
| SCHEMBL21110440 | 0.86 | EGFR (0.81) | EGFRITKSYKMAPK8MAPK9 | |
| SCHEMBL21109601 | 0.86 | EGFR (0.66) | EGFRITKSYKMTNR1AMTNR1B | |
| SCHEMBL3170157 | 0.86 | MAPK8 (0.79) | EGFRITKSYKMAPK8MAPK9 | |
| SCHEMBL915061 | 0.85 | EGFR (0.67) | EGFRITKSYKMAPK8MAPK9 | |
| SCHEMBL12518559 | 0.84 | EGFR (1.00) | EGFRITKSYKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | EGFR 966/4885ITK 59/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.